About orgenesis inc - ORGS
Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies, and services in the cell and gene therapy industry. It operates through the following segments: Octomera and Therapies. The Octomera segment refers to the point of care services. The Therapies segment is involved in therapeutic development operations. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.
ORGS At a Glance
Orgenesis, Inc.
20271 Goldenrod Lane
Germantown, Maryland 20876
| Phone | 1-480-659-6404 | Revenue | 1.04M | |
| Industry | Packaged Software | Net Income | -48,165,000.00 | |
| Sector | Technology Services | 2024 Sales Growth | 95.283% | |
| Fiscal Year-end | 12 / 2025 | Employees | 77 | |
| View SEC Filings |
ORGS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 7.689 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.066 |
| Enterprise Value to Sales | 24.636 |
| Total Debt to Enterprise Value | 0.716 |
ORGS Efficiency
| Revenue/Employee | 13,441.558 |
| Income Per Employee | -625,519.481 |
| Receivables Turnover | 25.875 |
| Total Asset Turnover | 0.13 |
ORGS Liquidity
| Current Ratio | 0.028 |
| Quick Ratio | 0.028 |
| Cash Ratio | 0.026 |
ORGS Profitability
| Gross Margin | -224.638 |
| Operating Margin | -2,513.527 |
| Pretax Margin | -4,726.184 |
| Net Margin | -4,653.623 |
| Return on Assets | -605.735 |
| Return on Equity | N/A |
| Return on Total Capital | 250.312 |
| Return on Invested Capital | N/A |
ORGS Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -94.891 |
| Total Debt to Total Assets | 1,351.517 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -50.837 |